These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26892929)

  • 1. Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug-drug interactions (DDIs) with improved adherence and tolerability.
    Mulka L; Annandale D; Richardson C; Fisher M; Richardson D
    Sex Transm Infect; 2016 Mar; 92(2):107. PubMed ID: 26892929
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of Triple Combination Antiretroviral Therapy With Raltegravir as Empiric HIV Therapy in the High-risk HIV-exposed Newborn.
    Trahan MJ; Lamarre V; Metras ME; Kakkar F
    Pediatr Infect Dis J; 2019 Apr; 38(4):410-412. PubMed ID: 30882734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County.
    Beymer MR; Kofron RM; Tseng CH; Bolan RK; Flynn RP; Sayles JM; Perez MJ; Jordan WC; Landovitz RJ
    Int J STD AIDS; 2018 May; 29(6):557-562. PubMed ID: 29183270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
    Leal L; León A; Torres B; Inciarte A; Lucero C; Mallolas J; Laguno M; Martínez-Rebollar M; González-Cordón A; Manzardo C; Rojas J; Pich J; Arnaiz JA; Gatell JM; García F;
    J Antimicrob Chemother; 2016 Jul; 71(7):1987-93. PubMed ID: 26994089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice.
    Emiliozzi A; Ciccullo A; Borghetti A; Picarelli C; Farinacci D; Baldin G; Di Giambenedetto S
    HIV Med; 2020 Feb; 21(2):e1-e2. PubMed ID: 31338932
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of HIV post-exposure prophylaxis in forensic medicine following incidents of sexual violence in Hamburg, Germany: a retrospective study.
    Ebert J; Sperhake JP; Degen O; Schröder AS
    Forensic Sci Med Pathol; 2018 Sep; 14(3):332-341. PubMed ID: 29777425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant intolerability of efavirenz in HIV occupational postexposure prophylaxis.
    Wiboonchutikul S; Thientong V; Suttha P; Kowadisaiburana B; Manosuthi W
    J Hosp Infect; 2016 Apr; 92(4):372-7. PubMed ID: 26876748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HIV prophylaxis kits. A concept for emergency treatment in the context of postexposure prophylaxis].
    Wicker S; Walcher F; Wutzler S; Marzi I; Stephan C
    Chirurg; 2014 Jan; 85(1):60-2. PubMed ID: 24292193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to HIV Postexposure Prophylaxis in a Major Hospital in Northwestern Nigeria.
    Dayyab FM; Iliyasu G; Habib AG
    Infect Control Hosp Epidemiol; 2018 Feb; 39(2):247-248. PubMed ID: 29291753
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV.
    Kreutzwiser D; Sheehan N; Dayneka N; Lemire B; Wong A; Samson L; Brophy J
    Antivir Ther; 2017; 22(6):545-549. PubMed ID: 28198351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?
    Cattaneo D; Puoti M; Sollima S; Moioli C; Foppa CU; Baldelli S; Clementi E; Gervasoni C
    J Antimicrob Chemother; 2016 May; 71(5):1341-5. PubMed ID: 26755497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is PEP prescribed appropriately?
    Whitlock G; Nwokolo N; McOwan A
    HIV Med; 2015 Sep; 16(8):519-20. PubMed ID: 26245890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence and Characteristics of HIV Post-Exposure Prophylaxis for a Population in Tel Aviv of Men who have Sex with Men.
    Oz N; Alon D; Stein GY; Turner D
    Isr Med Assoc J; 2017 Apr; 19(4):257-261. PubMed ID: 28480682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
    McAllister J; Read P; McNulty A; Tong WW; Ingersoll A; Carr A
    HIV Med; 2014 Jan; 15(1):13-22. PubMed ID: 24007390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antiretroviral prophylaxis after non-occupational exposure to HIV in Abidjan (Cote d'Ivoire)].
    Ehui E; Tanon A; Guié P; Aba T; Toa-Lou C; Kassi A; Ouattara I; Kouakou G; Mossou C; Kakou A; Eholié S; Aoussi E; Bissagnéné E
    Med Mal Infect; 2010 Oct; 40(10):574-81. PubMed ID: 20554137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raltegravir is safely used with long-term viral suppression for HIV-infected patients on hemodialysis: a pharmacokinetic study.
    Yanagisawa K; Nagano D; Ogawa Y; Uchiumi H; Shigehara T; Saruki K; Handa H; Araki T; Yamamoto K; Nojima Y
    AIDS; 2016 Mar; 30(6):970-2. PubMed ID: 26959356
    [No Abstract]   [Full Text] [Related]  

  • 17. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis.
    Kuhar DT; Henderson DK; Struble KA; Heneine W; Thomas V; Cheever LW; Gomaa A; Panlilio AL;
    Infect Control Hosp Epidemiol; 2013 Sep; 34(9):875-92. PubMed ID: 23917901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does dropping day 5 PEP follow-up affect outcomes? An audit of HIV post-exposure prophylaxis at a central London sexual health clinic.
    O'Keeffe C; Nwokolo N; McOwan A; Whitlock G
    Int J STD AIDS; 2015 Jul; 26(8):590-2. PubMed ID: 25122580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.
    Kovarova M; Swanson MD; Sanchez RI; Baker CE; Steve J; Spagnuolo RA; Howell BJ; Hazuda DJ; Garcia JV
    J Antimicrob Chemother; 2016 Jun; 71(6):1586-96. PubMed ID: 27002074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing adherence to preexposure and postexposure prophylaxis: the need for an integrated biobehavioral approach.
    Blashill AJ; Ehlinger PP; Mayer KH; Safren SA
    Clin Infect Dis; 2015 Jun; 60 Suppl 3(Suppl 3):S187-90. PubMed ID: 25972502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.